Protective Properties Of The Aqueous Extract Of Saffron (Crocus Sativus L.) In Ischemic Stroke, Randomized Clinical Trial
Notes for this study:
||HOMA β ( %) Mean and SD. Placebo: before 60.9 (28.5), after 29.0 (17.4). Crocin: before 56.1 (28.4), after 43.1 (24.5) . Saffron: before 58.5 (23.6) , after 29.1 (12.8) .
|Number of Subjects
||18-29, 30-44, 45-64
In a randomized, triple-blind trial, 66 male participants with schizophrenia took 30 mg of saffron, crocin, or placebo daily for 12 weeks, all in combination with olanzapine. There was less of an increase in fasting glucose in the supplement groups than placebo. There weren't meaningful differences for lipid profile, waist circumference, blood pressure, insulin resistance, HbA1C, and fasting insulin.
The trial was preregistered: IRCT2013020312351N1 and IRCT2013081912351N2